ToxPoint: The case for Equilibrative Nucleoside Transporters in current regulatory guidance. [PDF]
Martinez-Guerrero L +4 more
europepmc +1 more source
Old Drug, New Science: Metformin and the Future of Pharmaceutics. [PDF]
Caturano A +8 more
europepmc +1 more source
Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors. [PDF]
Stromatt JC +6 more
europepmc +1 more source
Metformin in Colorectal Cancer: Epidemiological Evidence, Predictive Biomarkers, and Implications for Prevention and Treatment. [PDF]
Myung S, Park YY, Kim MS.
europepmc +1 more source
The Effect of MATE1 Polymorphisms on Cisplatin Efficacy in the Treatment of Head and Neck Cancer
Mahler, M +8 more
openaire +3 more sources
Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium). [PDF]
Asano S +8 more
europepmc +1 more source
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
Multidrug and toxin extrusion 1 (MATE1/SLC47A1) is expressed in the brush-border membrane of renal proximal tubules and mediates the efflux of cationic drugs. In the present study, the role of MATE1 in the nephrotoxicity of cisplatin was investigated in vivo and in vitro.
openaire
A strategy for evaluating the impact of processing of Chinese meteria medica on meridian tropism: the influence of salt-water processing of phellodendri chinensis cortex on renal transport proteins. [PDF]
Chen Y +8 more
europepmc +1 more source
Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants. [PDF]
Chang J +13 more
europepmc +1 more source
Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance. [PDF]
Sebata A +8 more
europepmc +1 more source

